If you see, if you recall, most of the API and chemical companies were trading at a much superior valuation to, let us say, that of a formulation companies in the pharmaceutical sector, that was never the case in the last 15-20 years.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the
September 8, 2026